Trisalus Life Sciences, Inc. ( (TLSI) ) has released its Q4 earnings. Here is a breakdown of the information Trisalus Life Sciences, Inc. presented to its investors.
TriSalus Life Sciences, Inc. is an oncology-focused medical technology company that integrates innovative delivery technology with standard-of-care therapies to improve outcomes for patients with solid tumors. The company recently reported its financial results for the fourth quarter and full year of 2024, showcasing significant revenue growth and strategic advancements.
In 2024, TriSalus Life Sciences achieved a revenue of $29.4 million, marking a 59% increase from the previous year. The company also reported a gross margin of 86% for the full year. TriSalus has reaffirmed its 2025 guidance, expecting over 50% revenue growth, a reduction in operating expenses by more than 20%, and positive EBITDA and cash flow in the second half of 2025.
Key highlights from the company’s recent activities include the expansion of its product portfolio with the launch of the TriNav LV Infusion System and TriGuide Guiding Catheter, aimed at optimizing therapeutic delivery for patients with larger vessels. Additionally, TriSalus is advancing its DELIVER clinical program to demonstrate the efficacy of its PEDD technology in treating complex cancer cases. The company also completed enrollment for the PERIO-03 Phase 1 trial for pancreatic cancer treatment and presented positive results from the PERIO-01 trial for uveal melanoma liver metastases.
Looking ahead, TriSalus Life Sciences remains focused on achieving its financial targets for 2025, driven by market share increases and the commercial launch of new products. The company is also exploring strategic partnerships to further its clinical programs and expand its addressable market, positioning itself for continued growth and innovation in the oncology sector.